
IMPAACT Research Agenda

2023 - 2027





Revised Scientific Aims

2 3 4

2

Advance **treatment during pregnancy and postpartum**, aiming to optimize maternal and child health outcomes and accelerate the evaluation (pharmacokinetics (PK), safety, antiviral efficacy), licensure and optimal use of **potent and durable ARVs and other therapeutics** for pregnant people and infants, children, and adolescents with HIV and related diseases and conditions

Evaluate the potential for **ART-free HIV remission** through therapeutic interventions aimed at prevention, clearance and post-treatment control of HIV reservoirs in infants, children and adolescents with HIV and leverage expertise for evaluation of **vaccines** for HIV and related/co-occurring conditions in these populations

Evaluate novel approaches for **TB prevention**, **diagnosis and treatment** in infants, children, adolescents and pregnant and postpartum women with and without HIV that will lead to optimal dosing and regimens, licensing and decreased morbidity and mortality

Determine optimal and feasible biological and behavioral methods for the prevention and management of **neuropsychological and mental health complications of HIV and its treatment** in infants, children, adolescents and pregnant and postpartum people

Current Portfolio

Includes evaluation of the following interventions/agents:

Therapeutics

- DTG in Neonates, Infants, Children and Adolescents
- Selected ARV and TB drugs in Pregnant/ Postpartum People
- LA CAB/RPV in Children & Adolescents and in Pregnancy
- Oral PrEP (TDF/FTC) in Pregnancy & Postpartum
- GLE/PIB for Hepatitis C in Pregnancy

Brain and Mental Health


 Group-based Counseling Intervention in Treatment of Non-adherent Adolescents

HIV Cure and Immunotherapy

- LPV and NVP containing early intensive treatment, RAL and NVP containing early intensive treatment, and VRC01 in Infants
- Cord Blood Transplantation with CCR5Δ32 Donor Cells
- HIVconsvX Vaccines
- bNAbs in Infants and Children
- RSV Vaccines in Children

Tuberculosis

- VPM1002/BCG in Pre-Adolescents
- Pretomanid in Children
- RPT/INH in Children
- BDQ in Children
- DLM in Children
- Combination Regimen for RR-TB in Children



Current Portfolio

25 active studies

	3 Proposals Recently Approved	6 Protocols in Development	3 Pending and Open	10 Enrolling	1 in Follow- Up	2 Closed to Follow-Up*
Therapeutics	2043^	2041^, 2040^, 2037	2036	2026^, 2023, 2017	2009^	P1093
Tuberculosis	2020	2024	2035	2034, 2005, 2003B, P1108		
Brain and Mental Health			2016			
Cure and Immunotherapy	2042	2039, 2038		2028, 2021, P1115		P1107
Approximately 30 additional studies and ancillary studies (NWCS. DACS. DR)					*closed to follow	-up in the last year

Approximately 30 additional studies and ancillary studies (NWCS, DACS, DR) in the analysis and manuscript writing phase *closed to follow-up in the last year ^study during pregnancy/postpartum